Skip to Main Content

Paper Details

The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma.
Clin Cancer Res
6
2022
Cancer, Esophageal Adenocarcinoma, MDM2, Patients, TP53, TP53 dysfunction, adenocarcinoma of the lower esophagus or gastroesophageal junction, esophageal adenocarcinoma, genomic features, locally advanced esophageal adenocarcinoma, patients, tumor
Author NameAffiliation
Nikolaus SchultzCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Nikolaus SchultzCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Michael F BergerCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center
  • 1 - 3

Datasets

Release 1.2